San Jose, CA

Allergy and Asthma Associates of Santa Clara Valley Research Center

Asthma

Cough

Migraine Disorders

Chronic Cough

Zolmitriptan

SAR443765

BLU-5937

RPT193

Aerovant

GB001

Aerovance

Bellus Health

Gossamer Bio

RAPT Therapeutics

Sanofi

Tivic Health Systems

Zosano Pharma

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.

Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma

Allergy and Asthma Associates of Santa Clara Valley Research Center | San Jose, CA

Site insights

Work at this site?

Active trials

Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma (AIRCULES)

Trial sponsors